肾移植患儿术后应用糖皮质激素治疗研究现状

发布时间：2018-07-21 18:23

【摘要】：正糖皮质激素是肾移植患儿术后传统免疫抑制方案的核心药物。但是,长期应用糖皮质激素会导致诸多不良反应,包括库欣面容、高血压、高脂血症、类固醇糖尿病、感染、生长发育障碍、骨质疏松和移植后淋巴细胞增殖性疾病等~[1]。其中,生长发育迟缓和身材矮小尤其值得关注。此外,高血压、高脂血症和类固醇糖尿病等均可增加心血管疾病风险,甚至导致移植失败~[2]。因此,众多研究者开始致力于改进肾移植术后免疫抑制方案,探讨术后减少甚至无
[Abstract]:Glucocorticoid is the core drug of traditional immunosuppressive regimen after renal transplantation in children. However, long-term use of glucocorticoids can lead to a number of adverse reactions, including Cushing's face, hypertension, hyperlipidemia, steroid diabetes, infection, dysplasia of growth, osteoporosis and post-transplant lymphoproliferative diseases. Among them, growth retardation and short stature are of particular concern. In addition, hypertension, hyperlipidemia and steroid diabetes can increase the risk of cardiovascular disease and even lead to transplant failure. Therefore, many researchers began to work on improving immunosuppressive protocols after renal transplantation, and to explore the reduction or absence of post-operative immunosuppression.
【作者单位】：北京大学第一医院;
【分类号】：R726.9

【相似文献】